SE9803761D0 - Method to avoid increased iridial pigmentation during prostaglandin treatment - Google Patents

Method to avoid increased iridial pigmentation during prostaglandin treatment

Info

Publication number
SE9803761D0
SE9803761D0 SE9803761A SE9803761A SE9803761D0 SE 9803761 D0 SE9803761 D0 SE 9803761D0 SE 9803761 A SE9803761 A SE 9803761A SE 9803761 A SE9803761 A SE 9803761A SE 9803761 D0 SE9803761 D0 SE 9803761D0
Authority
SE
Sweden
Prior art keywords
iridial pigmentation
avoid increased
prostaglandin treatment
pigmentation during
prostaglandin
Prior art date
Application number
SE9803761A
Other languages
English (en)
Inventor
Johan Stjernschantz
Bahram Resul
Original Assignee
Synphora Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synphora Ab filed Critical Synphora Ab
Priority to SE9803761A priority Critical patent/SE9803761D0/sv
Publication of SE9803761D0 publication Critical patent/SE9803761D0/sv
Priority to PCT/SE1999/001993 priority patent/WO2000025771A1/en
Priority to AU14350/00A priority patent/AU758973B2/en
Priority to EP99971315A priority patent/EP1126835A1/en
Priority to CA002349427A priority patent/CA2349427A1/en
Priority to JP2000579212A priority patent/JP2002528491A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SE9803761A 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment SE9803761D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE9803761A SE9803761D0 (sv) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment
PCT/SE1999/001993 WO2000025771A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
AU14350/00A AU758973B2 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
EP99971315A EP1126835A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
CA002349427A CA2349427A1 (en) 1998-11-04 1999-11-04 Method for preventing increased iridial pigmentation during prostaglandin treatment
JP2000579212A JP2002528491A (ja) 1998-11-04 1999-11-04 プロスタグランジン治療の間の虹彩の色素沈着の増加を予防する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9803761A SE9803761D0 (sv) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment

Publications (1)

Publication Number Publication Date
SE9803761D0 true SE9803761D0 (sv) 1998-11-04

Family

ID=20413170

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9803761A SE9803761D0 (sv) 1998-11-04 1998-11-04 Method to avoid increased iridial pigmentation during prostaglandin treatment

Country Status (6)

Country Link
EP (1) EP1126835A1 (sv)
JP (1) JP2002528491A (sv)
AU (1) AU758973B2 (sv)
CA (1) CA2349427A1 (sv)
SE (1) SE9803761D0 (sv)
WO (1) WO2000025771A1 (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AU754064B2 (en) * 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
WO2002085248A2 (en) * 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoids augment ocular drug penetration
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
MXPA01013257A (es) * 2001-12-18 2003-06-25 Arturo Jimenez Bayardo Suspension oftalmica de rofecoxib para el tratamiento de la inflamacion y el dolor ocular.
ATE546143T1 (de) * 2002-08-29 2012-03-15 Santen Pharmaceutical Co Ltd Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
JP4314433B2 (ja) 2002-11-18 2009-08-19 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
CA2562356A1 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
CA2932130C (en) * 2011-01-07 2019-07-09 Allergan, Inc. Compositions comprising substituted benzaldehydes and use thereof for lightening skin or treating hyperpigmenation and hypermelanosis disorders
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53127832A (en) * 1977-04-11 1978-11-08 Teijin Ltd Antiphkogistics for oral administration containing thiaprostaglandins
GB2135881A (en) * 1983-03-02 1984-09-12 Erba Farmitalia Method and pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs
GB8625325D0 (en) * 1986-10-22 1986-11-26 Glaxo Group Ltd Chemical compounds
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
AU8089091A (en) * 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition containing ibuprofen and a prostaglandin
EP0527887B1 (en) * 1990-05-03 1995-04-26 G.D. Searle & Co. Pharmaceutical composition
CA2182228C (en) * 1994-01-28 2008-09-16 Paul Ashton Codrugs as a method of controlled drug delivery
SE9702706D0 (sv) * 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Also Published As

Publication number Publication date
AU758973B2 (en) 2003-04-03
WO2000025771A1 (en) 2000-05-11
CA2349427A1 (en) 2000-05-11
EP1126835A1 (en) 2001-08-29
JP2002528491A (ja) 2002-09-03
AU1435000A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
SE9803761D0 (sv) Method to avoid increased iridial pigmentation during prostaglandin treatment
DK1075265T3 (da) Anvendelse af tetracycliner til behandling af sygdom i de Meibomske kirtler
EA200401043A1 (ru) Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm )
BRPI0009956A (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
DE69021214D1 (de) Orale zusammensetzung für die behandlung intestinaler entzündlicher krankheiten.
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE69329856D1 (de) Ester derivate von 4-aza-steroiden
MXPA03010146A (es) Composiciones de lipidos hipotensivos (derivados de prostaglandina) y timolol, y metodos para usar las mismas.
ATE234090T1 (de) Kombination von duloxetin mit nichtsteroid- entzündungshemmern für die behandlung von schmerz
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
DK0902789T3 (da) Androstenderivater
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
DE60227278D1 (de) Pharmazeutische zubereitungen für die behandlung von läsionen der haut und schleimhäute und diese verwendende verfahren und kits
DE69528602T2 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
ATE241363T1 (de) Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
SE0002211D0 (sv) Methods and compositions for prevention of myopia
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid